BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37568909)

  • 21. Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.
    Burel-Vandenbos F; Turchi L; Benchetrit M; Fontas E; Pedeutour Z; Rigau V; Almairac F; Ambrosetti D; Michiels JF; Virolle T
    Neuro Oncol; 2013 Oct; 15(10):1278-88. PubMed ID: 23935154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
    Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
    J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
    Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
    Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
    J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
    Pang B; Durso MB; Hamilton RL; Nikiforova MN
    Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.
    Ames HM; Rooper LM; Laterra JJ; Eberhart CG; Rodriguez FJ
    J Neuropathol Exp Neurol; 2018 May; 77(5):374-382. PubMed ID: 29490065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
    Yoshida A; Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Hiraoka N; Narita Y; Ichimura K
    Histopathology; 2019 Jan; 74(2):350-354. PubMed ID: 30221786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
    Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
    Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR as a clinical marker in glioblastomas and other gliomas.
    Saadeh FS; Mahfouz R; Assi HI
    Int J Biol Markers; 2018 Jan; 33(1):22-32. PubMed ID: 28885661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
    Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
    Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
    Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
    J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.